Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Collaborative Research and Development Grants

University of Waterloo

$5,406.00

Developing membrane platform technology for manufacturing of clinical-grade bioproducts

FY 2011-12

Summary
Biomanufacturing processes often contain three major components, namely upstream strain development, midstream cell cultivation, and downstream purification processing. Biological cells with an enhanced ability for the production of desired bioproducts, either ribosomal or non-ribosomal, are isolated or genetically constructed. They are then cultivated in bioreactors for multiplication. Following cultivation, a series of downstream processing steps are adopted for bioproduct purification. While construction of production strains is generally recognized as a key prerequisite for successful bioprocess development, downstream processing could account for a big portion of the capital and operation costs of the overall bioprocess. Hence, developing strategies for effective downstream processing becomes a challenging task for bioengineers. Nysa Membrane Technologies, Inc. is a Canadian company in possession of a novel, proprietary membrane-based platform technology with broad global applications in protein purification and other biological and industrial separations. By establishing the hydrogel technologies which can complement technical limitations associated with pure polymeric membranes, the company has so far developed several hydrogel membrane products for clarification (i.e. microfiltration), chromatography (i.e. anion/cation exchange), and concentration (i.e. ultrafiltration) steps. These products have special features, such as high flux, high binding capacity, and high mechanical strength, based on which they are able to outperform many existing commercial products. Recognizing the lack of commercial membrane products practically applied for manufacturing of clinical-grade bioproducts, the company is interested in commercializing their products by targeting the global market in biopharmaceutical and plasmid DNA manufacturing. To this end, the company will need to establish their platform technology as a superior alternative to the conventional one for bioproduct purification. This is the primary goal of the proposed project, a collaborative work between Nysa and University of Waterloo.
Program
Collaborative Research and Development Grants
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
363823-2007
Name nom
Chou, CPerry
Department département
Chemical Engineering
Organization id
33
Institution établissement
University of Waterloo
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2011
Competition year année de concours
2007
Award amount
5406
Program id
CRDPJ
Program nane en
Collaborative Research and Development Grants
Program name fr
Subventions de recherche et développement coopérative
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
500
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Manufacturing processes and products
Area of application fr
Procédés et produits industriels
Research subject code
1802
Research subject group en
Chemical engineering
Research subject group fr
Génie chimique
Research subject en
Biochemical engineering
Research subject fr
Génie biochimique
Partie
3
Nb partie
3
Application title
Developing membrane platform technology for manufacturing of clinical-grade bioproducts
Keyword
NSERC
Application summary
Biomanufacturing processes often contain three major components, namely upstream strain development, midstream cell cultivation, and downstream purification processing. Biological cells with an enhanced ability for the production of desired bioproducts, either ribosomal or non-ribosomal, are isolated or genetically constructed. They are then cultivated in bioreactors for multiplication. Following cultivation, a series of downstream processing steps are adopted for bioproduct purification. While construction of production strains is generally recognized as a key prerequisite for successful bioprocess development, downstream processing could account for a big portion of the capital and operation costs of the overall bioprocess. Hence, developing strategies for effective downstream processing becomes a challenging task for bioengineers. Nysa Membrane Technologies, Inc. is a Canadian company in possession of a novel, proprietary membrane-based platform technology with broad global applications in protein purification and other biological and industrial separations. By establishing the hydrogel technologies which can complement technical limitations associated with pure polymeric membranes, the company has so far developed several hydrogel membrane products for clarification (i.e. microfiltration), chromatography (i.e. anion/cation exchange), and concentration (i.e. ultrafiltration) steps. These products have special features, such as high flux, high binding capacity, and high mechanical strength, based on which they are able to outperform many existing commercial products. Recognizing the lack of commercial membrane products practically applied for manufacturing of clinical-grade bioproducts, the company is interested in commercializing their products by targeting the global market in biopharmaceutical and plasmid DNA manufacturing. To this end, the company will need to establish their platform technology as a superior alternative to the conventional one for bioproduct purification. This is the primary goal of the proposed project, a collaborative work between Nysa and University of Waterloo.
University of Waterloo - $5,406 Grant (2011-12) | Canada Spends